Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations
Overview
The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.
Full Title of Study: “Biology of Cerebral Arteriovenous Malformations : Study of the Link Between Blood Biomarkers and the Haemorrhagic Prognosis of Cerebral Arteriovenous Malformations”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: November 19, 2028
Clinical Trial Outcome Measures
Primary Measures
- Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic
- Time Frame: 6 months
- associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome
- Associaton between dosage of platelet and the arteriovenous malformation pronostic
- Time Frame: 6 months
- Dosage of platelet in blood samples and correlation with clinical outcome
- Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic
- Time Frame: 6 months
- Dosage of neutrophilic in blood samples and correlation with clinical outcome
- Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic
- Time Frame: 6 months
- Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome
Participating in This Clinical Trial
Inclusion Criteria
- Patient over 18 years old – Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring – Express consent to participate in the study And – children – Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority Exclusion Criteria:
- Patient benefiting from a legal protection measure – Pregnant or breast feeding woman
Gender Eligibility: All
Minimum Age: 0 Years
Maximum Age: N/A
Investigator Details
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Provider of Information About this Clinical Study
- Sponsor
- Overall Contact(s)
- Amélie Yavchitz, 01 48 63 64 54, ayavchitz@for.paris
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.